The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).
 
Pascal Hammel
Consulting or Advisory Role - AstraZeneca (Inst); ERYTECH Pharma (Inst); IPSEN (Inst); Mylan; Rafael Pharmaceuticals; VECT-HORUS
Speakers' Bureau - AstraZeneca; Mylan; SERVIER
Research Funding - AstraZeneca (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Halozyme; Ipsen; Pfizer/EMD Serono; Shire; Vect-Horus
 
Iman El-Hariry
Employment - ERYTECH Pharma
Leadership - ERYTECH Pharma
Stock and Other Ownership Interests - ERYTECH Pharma
Travel, Accommodations, Expenses - ERYTECH Pharma
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Genzyme; Incyte; Ipsen; Lilly; Medscape; Menarini; MSD; Novocure; Paraxel; PPD; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Swedish Orphan Biovitrum; Zymeworks
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; Advanz Pharma; AstraZeneca (I); Bayer; Boehringer Ingelheim (I); Bristol-Myers Squibb (I); Gilead Sciences (I); HMP; Ipsen; Lilly (I); MERCK; Merck (I); Midatech Pharma; MSD; NOVARTIS; PFIZER; PharmaMar; PharmaMar (I); Pierre Fabre; ROCHE; Roche (I); Sanofi; SERVIER; SERVIER (I); Sysmex (I)
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; HMP; Ipsen; Merck; MSD; Novartis; Pfizer; PharmaMar; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck; Roche
 
Jean-Philippe Metges
Honoraria - BMS; Lilly; Novartis; Sanofi; SynCoreBio
Travel, Accommodations, Expenses - Amgen; Amgen; LEO Pharma; MSD Oncology; MSD Oncology; MSD Oncology
 
Olivier Bouché
Consulting or Advisory Role - AstraZeneca; GRUNENTHAL; Merck Serono; MSD Oncology; Roche
Speakers' Bureau - Amgen; Bayer; Merck Serono; Pierre Fabre; Roche; Sanofi; Servier
 
Fabienne Portales
No Relationships to Disclose
 
Roberto A. Pazo Cid
No Relationships to Disclose
 
Laurent Mineur
No Relationships to Disclose
 
Antonio Manuel Cubillo Gracian
No Relationships to Disclose
 
Isabelle Trouilloud
No Relationships to Disclose
 
Rosine Guimbaud
Consulting or Advisory Role - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; SERVIER
Travel, Accommodations, Expenses - BMS
 
David Tougeron
Honoraria - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Merck Serono; MSD; Roche; Sanofi; Servier/Pfizer
Consulting or Advisory Role - AstraZeneca; MSD; Pierre Fabre; Sanofi
Research Funding - AstraZeneca (Inst); BTG (Inst); MSD (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Sanofi
 
Juan Jose Reina Zoilo
No Relationships to Disclose
 
Jaime Feliu
No Relationships to Disclose
 
Tamara Sauri
No Relationships to Disclose
 
Christos Fountzilas
Research Funding - Astellas Pharma (Inst); Corcept Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst)
 
Richard Kay
Consulting or Advisory Role - 4SC; Alvotech; AM Pharma; AstraZeneca; Atrivia; AXON Neuroscience; Basilea Pharmaceutical; Biogen; Biogen; BioNTech; Chiesi; Cyclaxel; Diurnal; Eisai Europe; EnteroBiotix; ERYTECH Pharma; Future Medicine; G1 Therapeutics; Gilead Sciences; IntraBio; Kyowa Kirin International; Lilly; Mereo BioPharma; MGB Biopharma; Minoryx; Novella Clinical; Novimmune; Otsuka; Pfizer; Recordati; Reneo Pharmaceuticals; Seres Therapeutics; Shenyang Tonglian Pharmaceutical; Steba Biotech; Synimmune; Theradex; Tyme; Vivifi
 
Hagop Youssoufian
No Relationships to Disclose
 
Manuel Hidalgo
No Relationships to Disclose